Here are relevant reports on : oncology-pharmaceuticals-therapeutics-arket
-
Lung Cancer Therapeutics Market (NSCLC & SCLC) - 2010-2020 (Pipeline Assessment and Market Forecast) in G7 countries
Lung cancer is responsible for most of the deaths (due to cancer) across the globe. With just one drug slated to be launched by 2014 – Talactoferrin by Agennix AG, for patients with advanced lung cancer; having failed both chemotherapy and treatments with epidermal growth factor receptor (EFGR) - Tyrosine kinase inhibitor (TKI). Lung cancer is still an area with high unmet need for early diagnosis and limited treatment options in the advanced stages of lung cancer.
- Published: November 2011
- Price: $ 4950
- TOC Available:
-
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market – (Pipeline Forecast & Market Forecast in G8 Countries) (2011 – 2020)
The incidence of acute lymphocytic leukemia is high in children from 0 to 14 years than the people aged above 14. It is the most common childhood acute lymphocytic leukemia. However, the acute lymphocytic leukemia may also occur in adults. Acute lymphocytic leukemia distribution depends on age. For instance, 30% of is diagnosed before the age of 5 and 55% of ALL age 15.The acute lymphocytic leukemia market is segmented into two types; namely childhood acute lymphocytic leukemia, and adult acute lymphocytic leukemia. The market was dominated by Hyper-CVAD regimen in 2010. However, in 2020, the market is expected to be equally dominated by Hyper-CVAD and Linker regimen.
- Published: December 2013
- Price: $ 4950
- TOC Available:
-
Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries (2010 - 2020)
Chronic lymphocytic leukemia is the second most common cancer in adult males and rarely occurs in children. The risk of chronic lymphocytic leukemia is closely associated with age. About 90% of chronic lymphocytic leukemia is diagnosed in middle age. Incidence rate of CLL is high in men and women over 50 years of age. The chronic lymphocytic leukemia market is segmented into two types; namely childhood chronic lymphocytic leukemia and adulthood lymphocytic leukemia. The market was dominated by Campath drug in 2010. However, in 2020, the market is expected to be equally dominated by GA101/RG7159 molecule and Arzerra drug.
- Published: December 2011
- Price: $ 4950
- TOC Available:
-
Acute Myeloid Leukemia Therapeutics Market in G8 Countries (2010 - 2020)
Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age. Incidence rate of acute myeloid leukemia is high in men and women over 50 years. The acute myeloid leukemia market is segmented into two types; namely childhood acute myeloid leukemia and adulthood acute myeloid leukemia. The market was dominated by AVD regimen in 2010. However, in 2020, the market is expected to be dominated by AVD regimen, Cyatarabine, and Quizartinib drug.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Global Nanomedical Devices and Therapeutics Market (2011-2016)
Nanomedicine, an application of nanotechnology in medical science, is an evolving market. It represents an important segment of nanotechnology which will significantly change the course of treating life threatening diseases. This, unlike other treatment options, is significantly expected to enhance efficacy and minimize overall adversities. Toxicity and environmental impact of nanoscale materials are the major problems nanomedicine. Research and development in nanomedicine is expected to offer a pool of novel products which will improve the health of patients. The robust product pipeline for nanobiomaterials poses a health picture of the market creates significant growth opportunities. However these will have to go through stringent testing protocols before commercialization.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC), Diagnostics Indication (Oncology, Neurology, Immunology), Therapeutic Products (Inhibitors, mAbs, CGT), Indication (Oncology, Rare Disease, Infectious) - Global Forecast to 2029
The global precision diagnostics and medicine market, valued at US$132.46 billion in 2023, stood at US$145.53 billion in 2024 and is projected to advance at a resilient CAGR of 11.1% from 2024 to 2029, culminating in a forecasted valuation of US$246.66 billion by the end of the period. Factors such as the growing integration of AI and ML to enhance precision diagnostics and medicine development supported by rising collaborations between pharmaceutical and diagnostics companies to improve precision healthcare and the rise in direct-to-consumer testing are driving the growth in the market.
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
Europe Medical Gas and Equipment Market by Type [Medical Gas (Oxygen, Nitrous Oxide), Medical Gas Equipment (Flowmeter, Others)], Application [Therapeutics, Diagnostics], End User [Hospital, Home Healthcare] - Regional Forecast to 2031
The Europe Medical Gas and Equipment Market, valued at US5D .71 billion in 2024, stood at USD 6.00 billion in 2025 and is projected to advance at a resilient CAGR of 5.3% from 2025 to 2031, culminating in a forecasted valuation of USD 8.19 billion by the end of the period. The Europe medical gas and equipment market is expanding because of factors such as healthcare demand resulting from an aging population, the prevalence of chronic and respiratory diseases, and higher surgical and ICU volumes.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Osteoarthritis Therapeutics Market by Anatomy (Knee, Hand), Drug Type (NSAIDs, Analgesics, Corticosteroids), Route of Administration (Parenteral), Distribution Channel (Hospital Pharmacies), Purchasing Pattern (Prescription Drugs) - Global Forecasts to 2025
The global osteoarthritis therapeutics market growth is primed to transition from USD 7.3 billion in 2020 to USD 11.0 million by 2025, showcasing a strong CAGR of 8.7%.
- Published: December 2020
- Price: $ 4950
- TOC Available:
-
Medical Gas and Equipment Market by Type [Medical Gas (Oxygen, Nitrous Oxide), Medical Gas Equipment (Flowmeter, Others)], Application [Therapeutics, Diagnostics], End User (Hospital, Home Healthcare]-Global Forecast to 2031
The medical gas and equipment market, valued at USD 19.90 billion in 2024, stood at USD 21.03 billion in 2025 and is projected to advance at a resilient CAGR of 6.2% from 2025 to 2031, culminating in a forecasted valuation of US$30.05 billion by the end of the period. The medical gas and equipment market is witnessing constant growth as a result of the rising demand for advanced healthcare services through hospitals, clinics, and homecare settings.
- Published: January 2026
- Price: $ 7150
- TOC Available:
-
Virus Filtration Market by Product (Kits & Reagents, Systems, Services), Application (Biologics (Vaccine & Therapeutics, Blood, Tissues, Stem Cells), Devices, Air, Water Purification), End User (Biopharmaceutical, CROs, Research) - Global Forecast to 2020
The global virus filtration market size is projected to grow at a CAGR of 12.3%. Virus filtration is an important operation in the pharmaceutical industry, as it not only ensures if the products are adequately purified and fit for consumption, but also helps to optimize process economics and prevent loss of valuable product.
- Published: April 2016
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
